A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD

PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

June 21, 2021

Primary Completion Date

June 12, 2023

Study Completion Date

June 12, 2023

Conditions
Alzheimer Disease
Interventions
DRUG

ACU193

Intravenous ACU193

DRUG

Placebo

Intravenous Placebo

Trial Locations (17)

10032

Columbia University, New York

19001

Abington Neurological Associates, Abington

28105

AMC Research, Matthews

30030

iResearch Atlanta, Decatur

30331

Atlanta Center for Medical Research, Atlanta

32159

Charter Research, Lady Lake

32321

Progressive Medical Research, Port Orange

32807

Combined Research Orlando Phase I-IV, Orlando

33009

Velocity Clinical Research, Hallandale

33125

Columbus Clinical Services, Miami

33615

Santos Research Center, Tampa

75231

Kerwin Medical Center, Dallas

77074

Clinical Trials Network, Houston

85258

Clinical Endpoints, Scottsdale

92663

Hoag Hospital Newport Beach, Newport Beach

92801

Orange County Research Institute, Anaheim

08755

Advanced Memory Research Institute of NJ, Toms River

Sponsors
All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Acumen Pharmaceuticals

INDUSTRY

NCT04931459 - A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD | Biotech Hunter | Biotech Hunter